MedTrace Logo

Hyperventilation and Physical Performance in Obesity

NCT07122804 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2026-04-09

No results posted yet for this study

Summary

Obesity has become a major public health concern worldwide due to its rapidly increasing prevalence. It is defined as an abnormal or excessive accumulation of body fat that may impair health. Obesity is associated not only with chronic conditions such as cardiovascular diseases, type 2 diabetes, osteoarthritis, and certain types of cancer, but also with impaired respiratory function.

Excess body mass can reduce the range of motion of the respiratory muscles, limit the mechanical function of the chest wall and diaphragm, and decrease the efficiency of ventilation. As a result, individuals with obesity often experience exertional shortness of breath, rapid breathing, and inadequate ventilation. These symptoms may be considered part of hyperventilation syndrome, which is characterized by altered respiratory control and influenced by both physiological and psychological factors.

Although some studies have reported the presence of hyperventilation symptoms in individuals with obesity, their impact on physical performance has not been adequately investigated. Hyperventilation can limit the ability to perform daily activities and may lead to fatigue, imbalance, and other problems that directly affect physical performance.

The aim of this study is to examine the relationship between hyperventilation symptoms and physical performance parameters in individuals with obesity. The findings are expected to contribute to a more comprehensive assessment of physical fitness in this population and to support the development of individualized physiotherapy interventions.

Conditions

Interventions

OTHER

Assessment

Within the scope of the study, without any intervention, data regarding the participants' hyperventilation symptoms and physical capacities will be evaluated.

Sponsors & Collaborators

  • Istinye University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-15
Primary Completion
2026-02-15
Completion
2026-02-28

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07122804 on ClinicalTrials.gov